JPWO2020230099A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020230099A5 JPWO2020230099A5 JP2021568319A JP2021568319A JPWO2020230099A5 JP WO2020230099 A5 JPWO2020230099 A5 JP WO2020230099A5 JP 2021568319 A JP2021568319 A JP 2021568319A JP 2021568319 A JP2021568319 A JP 2021568319A JP WO2020230099 A5 JPWO2020230099 A5 JP WO2020230099A5
- Authority
- JP
- Japan
- Prior art keywords
- crystalline form
- diffraction pattern
- ray powder
- powder diffraction
- pyridine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 15
- 229910017488 Cu K Inorganic materials 0.000 claims description 11
- 229910017541 Cu-K Inorganic materials 0.000 claims description 11
- 230000005855 radiation Effects 0.000 claims description 11
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000002441 X-ray diffraction Methods 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 26
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 26
- 235000005152 nicotinamide Nutrition 0.000 description 13
- 239000011570 nicotinamide Substances 0.000 description 13
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 125000004497 pyrazol-5-yl group Chemical group N1N=CC=C1* 0.000 description 8
- 229910002012 Aerosil® Inorganic materials 0.000 description 7
- HGCOOPLEWPBLOY-PFEQFJNWSA-N N-[4-[chloro(difluoro)methoxy]phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide hydrochloride Chemical compound Cl.O[C@@H]1CCN(C1)c1ncc(cc1-c1ccn[nH]1)C(=O)Nc1ccc(OC(F)(F)Cl)cc1 HGCOOPLEWPBLOY-PFEQFJNWSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 7
- 239000001913 cellulose Substances 0.000 description 7
- 229920002678 cellulose Polymers 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- 239000007888 film coating Substances 0.000 description 7
- 238000009501 film coating Methods 0.000 description 7
- 239000007916 tablet composition Substances 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- -1 carboxamide hydrochloride Chemical class 0.000 description 5
- 150000003857 carboxamides Chemical class 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 238000002156 mixing Methods 0.000 description 4
- 230000001568 sexual effect Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- VOVZXURTCKPRDQ-CQSZACIVSA-N n-[4-[chloro(difluoro)methoxy]phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-5-yl)pyridine-3-carboxamide Chemical compound C1[C@H](O)CCN1C1=NC=C(C(=O)NC=2C=CC(OC(F)(F)Cl)=CC=2)C=C1C1=CC=NN1 VOVZXURTCKPRDQ-CQSZACIVSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001757 thermogravimetry curve Methods 0.000 description 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- OBLVPWTUALCMGD-UHFFFAOYSA-N pyridin-1-ium-3-carboxamide;chloride Chemical compound Cl.NC(=O)C1=CC=CN=C1 OBLVPWTUALCMGD-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024045596A JP2024095697A (ja) | 2019-05-16 | 2024-03-21 | Ｎ－［４－（クロロジフルオロメトキシ）フェニル］－６－［（３ｒ）－３－ヒドロキシピロリジン－１－イル］－５－（１ｈ－ピラゾール－５－イル）ピリジン－３－カルボキサミドの結晶性形態 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962848857P | 2019-05-16 | 2019-05-16 | |
| US62/848,857 | 2019-05-16 | ||
| US201962949599P | 2019-12-18 | 2019-12-18 | |
| US62/949,599 | 2019-12-18 | ||
| PCT/IB2020/054628 WO2020230099A1 (en) | 2019-05-16 | 2020-05-15 | Crystalline forms of n-[4-(chlorodifluoromethoxy)phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-5-yl)pyridine-3-carboxamide |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024045596A Division JP2024095697A (ja) | 2019-05-16 | 2024-03-21 | Ｎ－［４－（クロロジフルオロメトキシ）フェニル］－６－［（３ｒ）－３－ヒドロキシピロリジン－１－イル］－５－（１ｈ－ピラゾール－５－イル）ピリジン－３－カルボキサミドの結晶性形態 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022532404A JP2022532404A (ja) | 2022-07-14 |
| JP2022532404A5 JP2022532404A5 (https=) | 2022-08-25 |
| JPWO2020230099A5 true JPWO2020230099A5 (https=) | 2022-08-25 |
Family
ID=70775449
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021568319A Withdrawn JP2022532404A (ja) | 2019-05-16 | 2020-05-15 | Ｎ－［４－（クロロジフルオロメトキシ）フェニル］－６－［（３ｒ）－３－ヒドロキシピロリジン－１－イル］－５－（１ｈ－ピラゾール－５－イル）ピリジン－３－カルボキサミドの結晶性形態 |
| JP2024045596A Pending JP2024095697A (ja) | 2019-05-16 | 2024-03-21 | Ｎ－［４－（クロロジフルオロメトキシ）フェニル］－６－［（３ｒ）－３－ヒドロキシピロリジン－１－イル］－５－（１ｈ－ピラゾール－５－イル）ピリジン－３－カルボキサミドの結晶性形態 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024045596A Pending JP2024095697A (ja) | 2019-05-16 | 2024-03-21 | Ｎ－［４－（クロロジフルオロメトキシ）フェニル］－６－［（３ｒ）－３－ヒドロキシピロリジン－１－イル］－５－（１ｈ－ピラゾール－５－イル）ピリジン－３－カルボキサミドの結晶性形態 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11407735B2 (https=) |
| EP (1) | EP3969117B1 (https=) |
| JP (2) | JP2022532404A (https=) |
| KR (1) | KR102945602B1 (https=) |
| CN (1) | CN114144232A (https=) |
| AU (1) | AU2020276701B2 (https=) |
| BR (1) | BR112021022712A2 (https=) |
| CA (1) | CA3139812A1 (https=) |
| CL (1) | CL2021003011A1 (https=) |
| IL (1) | IL287995A (https=) |
| MX (1) | MX2021013970A (https=) |
| TW (2) | TWI853027B (https=) |
| WO (1) | WO2020230099A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI853027B (zh) | 2019-05-16 | 2024-08-21 | 瑞士商諾華公司 | N-[4-(氯二氟甲氧基)苯基]-6-[(3r)-3-羥基吡咯啶-1-基]-5-(1h-吡唑-5-基)吡啶-3-甲醯胺之結晶形狀 |
| ES3057399T3 (en) | 2020-01-28 | 2026-03-02 | Tapi Czech Ind S R O | Solid state forms of asciminib and processes for the preparation thereof |
| WO2022206937A1 (zh) * | 2021-04-01 | 2022-10-06 | 苏州晶云药物科技股份有限公司 | 一种吡唑取代的烟酰胺类化合物的盐酸盐新晶型及其制备方法 |
| CN114369085B (zh) * | 2021-12-27 | 2023-01-03 | 武汉九州钰民医药科技有限公司 | 盐酸Asciminib的制备方法 |
| WO2024100212A1 (en) | 2022-11-10 | 2024-05-16 | Synthon B.V. | Crystalline form of asciminib hydrochloride |
| WO2024257116A1 (en) * | 2023-06-13 | 2024-12-19 | Natco Pharma Limited | Novel polymorphic forms of asciminib and its pharmaceutical salts thereof |
| WO2025032514A1 (en) * | 2023-08-07 | 2025-02-13 | Biophore India Pharmaceuticals Pvt. Ltd | A process for the preparation of solid forms of n-[4(chlorodifluoromethoxy)phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-3-yl) pyridine-3-carboxamide hydrogen chloride |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CO4920215A1 (es) | 1997-02-14 | 2000-05-29 | Novartis Ag | Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones |
| WO2001051919A2 (en) | 2000-01-07 | 2001-07-19 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| KR20150008406A (ko) | 2012-05-15 | 2015-01-22 | 노파르티스 아게 | Abl1, abl2 및 bcr-abl1의 활성을 억제하기 위한 벤즈아미드 유도체 |
| PT2861579T (pt) * | 2012-05-15 | 2018-04-27 | Novartis Ag | Derivados de benzamida para inibir a atividade de abl1, abl2 e bcr-abl |
| HUE031227T2 (en) | 2012-12-27 | 2017-07-28 | Zentiva Saglik Ueruenleri San Ve Tic A S | Dry granulation process for preparing metformin tablet compositions and compositions thereof |
| US10085993B2 (en) | 2014-07-25 | 2018-10-02 | Novartis Ag | Tablet formulation of 2-fluoro-N-methyl-4-[ 7-( quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide |
| WO2016100882A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
| EP3120851A1 (en) | 2015-07-21 | 2017-01-25 | Pangaea Biotech S.L. | 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers |
| US9931342B2 (en) | 2016-02-02 | 2018-04-03 | Duke University | Compositions and methods for the treatment of cancer |
| EP3292870A1 (en) | 2016-09-08 | 2018-03-14 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Fibronectin for use in the treatment of leukemia |
| EP3519400A1 (en) | 2016-09-27 | 2019-08-07 | Novartis AG | Surfactant systems for crystallization of organic compounds |
| EP3700516B1 (en) | 2017-10-27 | 2024-01-24 | Sonic Master Limited | Inhibitors of dux4 induction for regulation of muscle function |
| US20210214459A1 (en) | 2018-05-31 | 2021-07-15 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| TWI853027B (zh) | 2019-05-16 | 2024-08-21 | 瑞士商諾華公司 | N-[4-(氯二氟甲氧基)苯基]-6-[(3r)-3-羥基吡咯啶-1-基]-5-(1h-吡唑-5-基)吡啶-3-甲醯胺之結晶形狀 |
-
2020
- 2020-05-14 TW TW109116067A patent/TWI853027B/zh active
- 2020-05-14 TW TW113128176A patent/TW202444706A/zh unknown
- 2020-05-14 US US16/874,622 patent/US11407735B2/en active Active
- 2020-05-15 BR BR112021022712A patent/BR112021022712A2/pt unknown
- 2020-05-15 MX MX2021013970A patent/MX2021013970A/es unknown
- 2020-05-15 CA CA3139812A patent/CA3139812A1/en active Pending
- 2020-05-15 AU AU2020276701A patent/AU2020276701B2/en active Active
- 2020-05-15 EP EP20726959.8A patent/EP3969117B1/en active Active
- 2020-05-15 KR KR1020217040723A patent/KR102945602B1/ko active Active
- 2020-05-15 WO PCT/IB2020/054628 patent/WO2020230099A1/en not_active Ceased
- 2020-05-15 CN CN202080051576.4A patent/CN114144232A/zh active Pending
- 2020-05-15 JP JP2021568319A patent/JP2022532404A/ja not_active Withdrawn
-
2021
- 2021-11-10 IL IL287995A patent/IL287995A/en unknown
- 2021-11-15 CL CL2021003011A patent/CL2021003011A1/es unknown
-
2022
- 2022-07-06 US US17/858,701 patent/US12252478B2/en active Active
- 2022-07-06 US US17/858,713 patent/US12252479B2/en active Active
-
2024
- 2024-03-21 JP JP2024045596A patent/JP2024095697A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7456721B2 (ja) | ５－メチル－１－フェニル－２－（１ｈ）－ピリドンの顆粒製剤及びその製造方法 | |
| JP2022532404A5 (https=) | ||
| JP7660604B2 (ja) | ２，４，６－トリフルオロ－ｎ－［６－（１－メチル－ピペリジン－４－カルボニル）－ピリジン－２－イル］－ベンズアミドヘミコハク酸塩の大規模調製のためのプロセスおよび中間体、ならびに２，４，６－トリフルオロ－ｎ－［６－（１－メチル－ピペリジン－４－カルボニル）－ピリジン－２－イル］－ベンズアミド酢酸塩の調製 | |
| TW201944994A (zh) | 用於治療囊腫纖化症之醫藥組合物 | |
| US20220211705A1 (en) | Pharmaceutical compositions comprising afatinib | |
| TWI853027B (zh) | N-[4-(氯二氟甲氧基)苯基]-6-[(3r)-3-羥基吡咯啶-1-基]-5-(1h-吡唑-5-基)吡啶-3-甲醯胺之結晶形狀 | |
| CA2700844A1 (en) | Stable imatinib compositions | |
| JP2002513760A (ja) | パロキセチン固体分散体を製造するための水系方法 | |
| JP2018177815A (ja) | エスシタロプラム医薬組成物 | |
| US20170334860A1 (en) | Novel polymorphs of ivacaftor, process for its preparation and pharmaceutical composition thereof | |
| TWI884455B (zh) | １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶之製備方法及包含彼之醫藥組成物 | |
| WO2015199356A1 (en) | Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a process for the preparation thereof | |
| CN104098570A (zh) | 替卡格雷晶型及其制备方法和用途 | |
| JPWO2020230099A5 (https=) | ||
| JP2024542840A (ja) | Ｆｇｆｒ阻害剤の固体状形態 | |
| JP2018515566A (ja) | 医薬組成物 | |
| US20080234323A1 (en) | Amorphous and Three Crystalline Forms of Rimonabant Hydrochloride | |
| EP2236160A2 (en) | Modified release dimebolin formulations | |
| KR101578627B1 (ko) | 실로도신의 용출 특성이 향상된 약제학적 제제 | |
| RU2024129605A (ru) | Кристаллические формы n-[4-(хлордифторметокси)фенил]-6-[(3r)-3-гидроксипирролидин-1-ил]-5-(1h-пиразол-5-ил)пиридин-3-карбоксамида | |
| RU2021136800A (ru) | Кристаллические формы n-[4-(хлордифторметокси)фенил]-6-[(3r)-3-гидроксипирролидин-1-ил]-5-(1h-пиразол-5-ил)пиридин-3-карбоксамида | |
| KR102936055B1 (ko) | 제제 안정성이 향상된 테노포비르 알라펜아미드 함유 속방성 제제 | |
| JP7628020B2 (ja) | アキシチニブを有効成分とする医薬錠剤 | |
| JP2702284B2 (ja) | ソマトスタチン増加用またはソマトスタチン低下抑制用薬剤 | |
| JP2018020968A (ja) | ゲフィチニブを有効成分とする医薬組成物 |